![]() |
|
|
Vol. 304, Issue 1, 109-120, January 2003
Departments of Pharmacology (L.R.M., C.P.F.) and Psychiatry
(C.P.F.), The University of Texas Health Science Center at San Antonio,
San Antonio, Texas
Positive GABAA modulators and other sedatives, anxiolytics,
and anticonvulsants were used to evaluate mechanisms underlying the
discriminative stimulus effects of midazolam in untreated monkeys and
of flumazenil in monkeys treated with diazepam (5.6 mg/kg/day).
Positive GABAA modulators at benzodiazepine (e.g., flunitrazepam and abecarnil) and neuroactive steroid sites (e.g., androsterone) substituted for midazolam in all monkeys; the neuroactive steroids dihydroandrosterone and epipregnanolone substituted for midazolam in two of three monkeys. All positive GABAA
modulators attenuated flumazenil in diazepam-treated monkeys; doses of
flunitrazepam and abecarnil larger than doses substituting for
midazolam were required to attenuate flumazenil, whereas doses of
neuroactive steroids smaller than doses substituting for midazolam
attenuated flumazenil. Drugs with mechanisms that do not predominantly
involve allosteric modulation of GABA (e.g., buspirone, ketamine,
valproic acid, and diphenhydramine) did not substitute for midazolam or flumazenil. However, valproic acid enhanced the midazolam
discriminative stimulus and attenuated the flumazenil discriminative
stimulus; diphenhydramine attenuated the midazolam discriminative
stimulus. These results suggest that drugs not sharing a mechanism of
action with benzodiazepines can modulate the behavioral effects of
benzodiazepines. In addition, this study demonstrates that endogenous
ligands, presumably by acting at neuroactive steroid sites on the
GABAA receptor complex, share discriminative stimulus
effects with benzodiazepines. This study also suggests that positive
GABAA-modulating neuroactive steroids are especially potent
in attenuating behavioral effects that are related to diazepam withdrawal.
This article has been cited by other articles:
![]() |
C. Cohen, O. E. Bergis, F. Galli, A. W. Lochead, S. Jegham, B. Biton, J. Leonardon, P. Avenet, F. Sgard, F. Besnard, et al. SSR591813, a Novel Selective and Partial {alpha}4{beta}2 Nicotinic Receptor Agonist with Potential as an Aid to Smoking Cessation J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 407 - 420. [Abstract] [Full Text] [PDF] |
||||